AlzeCure will present the newly published data for their pain project against osteoartritis with their novel TrkA-NAM compound ACD137, and be talking about the unmet medical need and the potential opportunities for ACD137. Presenters will be Dr Märta Segerdahl, Dr Pontus Forsell and AlzeCure’s CEO Martin Jönsson.
More on the presentations will follow and additional information on TrkA-NAM and ACD137 can be found at AlzeCure Pharma’s web site: www.alzecurepharma.com
Fredrik Bengtsson, CEO, and Erik Bergelin, CFO, present the Q2-report for 2026 and answer questions from viewers.
Fredrik Meuller, President and CEO and Peter Welin, CFO and Deputy CEO will present the Q2 report for 2026 and answer questions during the Q&A.
Axel Berntsson, President & CEO, and Anna Åkerblad, CFO, will present the Q2 report for 2026 and answer questions during the Q&A.
For dialing in: +46850500829 , then enter the meeting ID: 879 5103 4389 followed by #.
Martin Edlund, CEO, will present the Q1 Presentation for 2026.
